These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 459005)

  • 21. Choices in creating continent urostomies following pelvic exenteration for gynecologic malignancies.
    Silver DF; Ashwell TR
    Gynecol Oncol; 2001 Sep; 82(3):510-5. PubMed ID: 11520148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduction of mortality and morbidity associated with pelvic exenteration.
    Karlen JR; Piver MS
    Gynecol Oncol; 1975 Jun; 3(2):164-7. PubMed ID: 1183867
    [No Abstract]   [Full Text] [Related]  

  • 23. Pelvic exenteration: complications of urinary diversion.
    Wrigley JV; Prem KA; Fraley EE
    J Urol; 1976 Oct; 116(4):428-30. PubMed ID: 1053328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA.
    Berek JS; Howe C; Lagasse LD; Hacker NF
    Gynecol Oncol; 2005 Oct; 99(1):153-9. PubMed ID: 16054678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Avoiding the Need for Bowel Anastomosis during Pelvic Exenteration-Urinary Sigmoid or Descending Colon Conduit-Short and Long Term Complications.
    Alemozaffar M; Nam CS; Said MA; Patil D; Carney KJ; David S; Master VA
    Urology; 2019 Jul; 129():228-233. PubMed ID: 30922975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urological complications after cystectomy as part of pelvic exenteration are higher than that after cystectomy for primary bladder malignancy.
    Brown KG; Solomon MJ; Latif ER; Koh CE; Vasilaras A; Eisinger D; Sved P
    J Surg Oncol; 2017 Mar; 115(3):307-311. PubMed ID: 27859276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pelvic exenteration as treatment of recurrent or advanced gynecologic and urologic cancer.
    Roos EJ; Van Eijkeren MA; Boon TA; Heintz AP
    Int J Gynecol Cancer; 2005; 15(4):624-9. PubMed ID: 16014116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional outcomes and complications of continent urinary diversions in patients with gynecologic malignancies.
    Ramirez PT; Modesitt SC; Morris M; Edwards CL; Bevers MW; Wharton JT; Wolf JK
    Gynecol Oncol; 2002 May; 85(2):285-91. PubMed ID: 11972389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pelvic exenteration: surgical aspects and analysis of early and late morbidity in a series of 106 patients.
    De Wever I
    Acta Chir Belg; 2011; 111(5):273-81. PubMed ID: 22191127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Urinary complications of pelvic exenterations for rectal cancer with urinary invasion].
    Gas J; Beauval JB; Chalret du Rieu M; Bou Nasr E; Philis A; Kirzin S; Thoulouzan M; Soulié M; Ghouti L
    Prog Urol; 2015 May; 25(6):348-54. PubMed ID: 25804429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Major complications following exenteration in cases of pelvic malignancy: a 10-year experience.
    Wydra D; Emerich J; Sawicki S; Ciach K; Marciniak A
    World J Gastroenterol; 2006 Feb; 12(7):1115-9. PubMed ID: 16534855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urinary conduit in pelvic cancer patients. A report of 16 years' experience.
    Swan RW; Rutledge FN
    Am J Obstet Gynecol; 1974 May; 119(1):6-13. PubMed ID: 4820911
    [No Abstract]   [Full Text] [Related]  

  • 33. Ileal conduit and continent ileocecal pouch for patients undergoing pelvic exenteration: comparison of complications and quality of life.
    Forner DM; Lampe B
    Int J Gynecol Cancer; 2011 Feb; 21(2):403-8. PubMed ID: 22964492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of surgeon volume on outcomes after pelvic exenteration for a gynecologic cancer.
    Jalloul RJ; Nick AM; Munsell MF; Westin SN; Ramirez PT; Frumovitz M; Soliman PT
    J Gynecol Oncol; 2018 Sep; 29(5):e68. PubMed ID: 30022632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surgical results of pelvic exenteration in the treatment of gynecologic cancer.
    Petruzziello A; Kondo W; Hatschback SB; Guerreiro JA; Filho FP; Vendrame C; Luz M; Ribeiro R
    World J Surg Oncol; 2014 Sep; 12():279. PubMed ID: 25200866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pelvic exenteration of gynecologic malignancy: indications, and technical and reconstructive considerations.
    Lambrou NC; Pearson JM; Averette HE
    Surg Oncol Clin N Am; 2005 Apr; 14(2):289-300. PubMed ID: 15817240
    [No Abstract]   [Full Text] [Related]  

  • 37. Performance and outcome of pelvic exenteration for gynecologic malignancies: A population-based study.
    Matsuo K; Mandelbaum RS; Adams CL; Roman LD; Wright JD
    Gynecol Oncol; 2019 May; 153(2):368-375. PubMed ID: 30792003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short-term outcomes after incontinent conduit for gynecologic cancer: comparison of ileal, sigmoid, and transverse colon.
    Tabbaa ZM; Janco JM; Mariani A; Dowdy SC; McGree ME; Weaver AL; Cliby WA
    Gynecol Oncol; 2014 Jun; 133(3):563-7. PubMed ID: 24704344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ileal conduit and continent ileocecal pouch for patients undergoing pelvic exenteration: comparison of complications and quality of life.
    Forner DM; Lampe B
    Int J Gynecol Cancer; 2011 Feb; 21(2):403-8. PubMed ID: 23077738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urological problems and the treatment of gynaecological cancer.
    Davies Q; Luesley DM
    Curr Opin Obstet Gynecol; 1998 Oct; 10(5):401-3. PubMed ID: 9818221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.